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ABBREVIATIONS AND SYMBOLS 
HPLC        -       High Performance Liquid Chromatography 
HPTLC     -      High Performance Thin Layer Chromatography 
ICH           -       International conference on harmonization 
LOD          -       Limit of detection 
LOQ          -      Limit of quantification 
min            -       Minute 
RP-HPLC  -      Reverse Phase - High Performance Liquid Chromatography 
RSD          - Relative standard deviation 
UV             - Ultra violet 
AS - Asymmetric factor 
gm          - Gram 
M                - Molar 
Mg              - Milligram 
ml              - Milliliter 
mM             - Millimolar 
mm             - Millimeter 
 N              - Normality 
ȝg             - Microgram 
ng             - Nano gram 
Rf                  - Retardation factor 
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Rs                 - Resolution 
Rt              - Retention time 
Tf                  - Tailing factor 
k` - capacity factor 
α - selectivity 
ȝl           - Microlitre 
Ȝmax            - Wavelength of maximum absorbance 
MET - Metformin 
TENE  - Teneligliptin 
WHO - World Health Organisation 
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1. INTRODUCTION  
 
 Analytical chemistry deals with methods for determining the chemical 
composition of samples of matter. Analytical chemistry consists of classical, wet 
chemical methods and modern, instrumental methods. Analytical chemistry has 
broad applications to forensics, medicine, science and engineering. 
I.  CLASSICAL METHODS1 
1. Qualitative methods 
2. Quantitative methods 
1. Qualitative methods 
A qualitative method yields information about the identity of atomic or 
molecular species or the functional groups in the sample. Identification may be 
based on differences in colour, odour, melting point, boiling point, radioactivity or 
reactivity. 
2. Quantitative methods 
 A quantitative method provides numerical information as to the relative 
amount of one or more of these components. It uses mass or volume changes to 
quantify amount. 
II.  INSTRUMENTAL METHODS 
 The instruments used for the analysis of methods are given below:  
 X – ray diffraction  
 UV – Visible Spectroscopy  
 Raman spectroscopy 
 Refractrometry 
 Polarimetry 
 Potentiometry 
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 Polarography 
 Conductometry 
 Mass spectrometry 
There are several valid reasons for developing new method of analysis: 
 Marketed drug may not be official in pharmacopoeias. 
 There may not be a suitable method for a particular analyte in the specific 
 sample matrix. 
 Existing methods may have poor accuracy and precision, too expensive, 
time consuming or energy intensive, not easily automated, does not 
provide adequate sensitivity or analyte selectivity in sample of interest. 
 Difficulties in extraction and separation process. 
 There may be a need for an alternative method to confirm, for legal or 
 scientific reasons, analytical data originally obtained by existing methods. 
III.  CHROMATOGRAPHY2 
Chromatography is essentially a group of techniques for the separation of 
the compounds of mixtures by their continuous distribution in two phases, one of 
which moving past the other. The systems associated with this definition are  
 A solid stationary phase and a liquid or gaseous mobile phase 
 (adsorption chromatography) 
 A liquid stationary phase and a liquid or gaseous mobile phase 
 (partition chromatography) 
 A solid polymeric stationary phase containing replaceable ions and 
 an ionic liquid mobile phase (ion exchange chromatography) 
 An inert gel which acts as a molecular sieve and a liquid mobile phase (gel 
chromatography) 
The basis of the separation of the components of a mixture may be defined 
in terms of one of these four modes of separation or by a combination. 
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1.  CHROMATOGRAPHY TECHNIQUES 
 The different chromatographic techniques include: 
 Thin layer chromatography 
 High performance thin layer chromatography 
 High performance liquid chromatography 
 Gas chromatography  
 Super critical fluid chromatography 
1.1. High Performance Thin Layer Chromatography3, 4 
 HPTLC is a sophisticated and automated form of TLC and is highly useful 
method for both qualitative and quantitative analysis. It allows for the various 
analytical applications which involve complex separation. The advantages of 
automation, scanning, full optimization, selective detection principle, minimum 
sample preparation, hyphenation, etc. enable it to be a powerful analytical tool for 
chromatographic information of complex mixtures of inorganic, organic, and 
biomolecules. It is a valuable tool for reliable identification providing 
chromatographic fingerprints.  
 
Various steps involved in HPTLC 
 
 
 
 
 
 
 
 
Selection of plate 
Sample and standard preparation 
Selection and optimization of mobile phase 
Application of standard and the sample 
Chromatographic development 
Detection of analytes 
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a.  Selection of plate 
 Pre-coated plates with various support material, sorbent layer and with 
various sorbent thickness of 100-250 m are used for quantitative and qualitative 
analysis. 
b.    Sample preparation 
 Sample preparation involves, dissolving the dosage form in a solvent with 
complete recovery of intact compounds of interest and minimum of matrix with 
suitable concentration of analyte during extraction and analysis must be 
considered and ensured. 
Choice of solvent for the sample: 
 It should dissolve the analytes. 
 It should be reasonably volatile. 
 It should have low viscosity. 
 It should be a weak (least polar) chromatographic solvent for the analyte. 
c. Sample application 
 This is the most critical step for obtaining good resolution for 
quantification by HPTLC. The sample solution should be applied through clean 
upper end of the capillary to marked point. Usually application of 0.5-5l for 
HPTLC is recommended. Samples are applied as bands, because it offers better 
separation and uniform after development. 
Advantages of auto sampler: 
 Even distribution of sample 
 Better resolution 
 Greater accuracy 
 Better separation 
 Larger quantities of sample can be handled for application 
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d. Optimization of mobile phase 
 Mobile phase should be chosen by considering chemical properties of 
analytes and the sorbent layer. Mobile phase ratio is selected by trial and error 
method. 
 
e. Chromatographic development 
 The chamber needs to be saturated prior to development, as solvent 
vaporizes soon. The time required for saturation will depend on the nature and 
composition of mobile phase and layer thickness. The precoated plate is then 
placed in the saturated chamber containing mobile phase and allowed to run the 
desired running distance and then kept out for drying.  
f. Detection 
 Detection under UV light is the first choice, as it is non – destructive in 
 most cases and employed for densitometric scanning. 
 Iodine is the universal detection reagent, the detection is usually non-
destructive and reversible but certain substances may be altered through 
non-reversible derivatization such as ethambutol hydrochloride, a totally 
non-UV absorbing compound. 
 Fluorescent chemicals are employed for detection of lipophilic substances 
 by wetting/non-wetting technique. 
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1.2.   High Performance Liquid Chromatography5-7 
A variety of methods are available for analysing pharmaceutical 
compounds; however high pressure liquid chromatography is currently the method 
of choice for the analysis of these compounds. HPLC offers high performance 
over ambient pressure or low pressure liquid chromatography. 
High performance liquid chromatography is used in analytical 
development to quantitate the active pharmaceutical ingredient (API) and to 
evaluate impurity and degradation product profiles of drug substance and drug 
products. Additional uses of HPLC include the determination of content 
uniformity of dosage forms, monitoring of dissolution profiles, determination of 
antioxidant and microbial preservative content and support of cleaning 
validations. Separations of these types require only a monitoring of one, or a 
limited number of predefined components. A significantly larger challenge is 
presented in the composite assays of drug substances and drug products where the 
goal is to quantitate API and relevant impurities and degradation products in a 
single chromatographic run.    
 The method development of pharmaceuticals by HPLC begins with array 
of methods suitable for the separation of drug substances, synthetic intermediates 
and starting materials, excipients, and products from forced decomposition 
studies.  
 The development of any new or improved method usually tailors existing 
approaches and instrumentation to the current analyte, as well as to the final needs 
or requirements of the method. Method development usually requires selecting the 
requirements and deciding on what type of instrumentation to utilize at the 
development stage, decisions regarding  
 Choice of column,  
 Mobile phase,  
 Detector(s) and  
 Method of quantitation must be addressed 
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Goals for new or improved HPLC method might include the following: 
 Qualitative identification of the specific analyte(s) of interest, providing 
some structural information to confirm general behaviour (i.e. retention 
time, pH ) 
 Quantitative determination, at trace levels when necessary (i.e. accurate, 
precise and reproducible in any laboratory setting when performed 
according to established procedures). 
 Ease of use, ability to be automated, high sample throughout and rapid 
sample turnaround time. 
 Sample preparation that minimizes time, effort, materials and volume of 
sample consumed. 
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The following criteria are to be met for developing methods: 
i. For drug substance 
 Methods should separate the API, synthetic process impurities, and drug 
substances degradation products. Methods should be able to detect impurities and 
degradation products present at levels greater than 0.05% relative to the API. 
Impurities and degradation products present at the levels greater than 0.1% should 
be identified and specifications should be placed on limits. 
ii. For drug products 
 Methods should separate the API, drug products degradation products 
from excipients. Drug products methods are not required to monitor synthetic 
process impurities, unless they are also drug product degradation products. 
Methods should be able to detect degradation products present at levels greater 
than 0.1% relative to the API. Degradation products present at levels greater than 
0.2% should be identified and specifications should be placed on limits. 
1.2.1. Fundamental Concepts 
 The fundamental concepts in HPLC include: 
a. Retention time 
 Retention time is the time of emergence of the peak maximum of a 
component after injection.   
The time between the sample injection point and analyte reaching a 
detector is called retention time (tR). The retention time of an unretained 
component (often marked by the first baseline disturbance caused by the elution of 
the sample solvent) is termed void time (t0). 
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 The height or the area of a peak is proportional to the concentration or the 
amount of that particular component in the sample. The peak area is most 
commonly used since it provides a more accurate quantitative measurement. 
 Chromatogram 
 
b. Capacity factor (k`) 
 A more fundamental term that measures the degree of retention of the 
analyte is the capacity factor or retention factor (k`), calculated by normalising the 
net retention time by the void time (t0). 
k` = tR - t0  / t0   
                                  Where  
                               k`  = capacity factor 
        tR  =  retention time 
                                                   t0   =  void time 
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c. Selectivity (α)  
 Separations between two components are possible if they have different 
migration rates through the column. Selectivity or separation factor is a measure 
of differential retention of two analytes.  
 Selectivity must be greater than 1.5 for peak separation. Selectivity is 
dependent on the nature of the stationary phase and the mobile phase composition. 
d. Column efficiency (N) 
 The term plate number (N), is a quantitative measure of the efficiency of 
the column and is related to the ratio of the retention time and the standard 
deviation of the peak width (σ). 
N = 16 X (tR /W) 
 Where  
   N = number of theoretical plates 
   tR = retention time 
   w = width of the peak 
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e. Height equivalent of a theoretical plate (HETP)  
 The concept of a plate is traditionally derived from the industrial 
distillation process using distillation columns consisting of individual plates were 
the condensing liquid is in equilibrium with the rising vapour. Thus, a longer 
distillation column would have more plates or equilibration steps. Similarly in 
chromatography, the HETP is equal to the length of the column (L) divided by the 
number of theoretical plates (N) even though there are no discrete plates inside the 
HPLC column. 
 Height equivalent of a theoretical plate, (HETP) = L / N 
     Where  
    L = length of the column 
              N = number of theoretical plates 
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f. Resolution (Rs) 
 The goal of most HPLC analysis is the separation of one or more analytes 
from other components in the sample in order to obtain quantitative information 
for each analyte. Resolution is the degree of separation of two adjacent peaks, and 
is defined as the difference in retention times of the two peaks divided by the 
average peak width. As peak widths of adjacent peaks tend to be similar, the 
average peak width can be equal to the width of one of the two peaks. 
Resolution, (Rs) = tR1 – tR2 / {(w1+ w2)/2} 
 Where 
  tR1 & tR2 - retention time of peaks 
  w1& w2 - width of the peaks 
Resolution: Chromatogram with two adjacent peaks  
 
g. Tailing factor (Tf) 
 Under ideal conditions, chromatographic peaks will have Gaussian peak 
shapes with perfect symmetry. In reality, most peaks are either slightly fronting or 
tailing. The tailing factor is defined by the USP, as a measure of peak asymmetry. 
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Tailing factors for most peaks should fall between 0.9 and 1.4, with a 
value of 1.0 indicating a perfectly symmetrical peak. Peak tailing is typically 
caused by adsorption or other strong interactions of the analyte with the stationary 
phase while peak fronting can be caused by column overloading, chemical 
reaction or isomerization during the chromatographic process. 
Tailing factor, Tf = AC / 2AB 
 
1.2.2. Mobile Phase Parameters 
a. Organic solvent and selectivity 
 Sample retention can be controlled by varying the solvent strength of the 
mobile phase. A strong solvent decreases retention and weak solvent increases 
retention. Tetrahydrofuran is stronger than acetonitrile, which in turn is stronger 
than methanol in RP – HPLC. 
b. Buffers 
 Many drugs have either acidic or basic functional groups and can exist in 
solutions in ionized or non – ionized forms. The ionic state and degree of 
ionization greatly affect their chromatographic retention in RP – HPLC. Typically, 
the ionic form does not partition well into the hydrophobic stationary phase and 
therefore has significantly lower capacity factor than the neutral, un-ionized form. 
Buffers are commonly used to control the pH of the mobile phase for the 
separation of acidic or basic analytes. 
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c. Acidic mobile phase  
 A mobile phase at acidic pH of 2.5 – 3 is a good starting point for most 
pharmaceutical applications because the low pH suppresses the ionization of most 
acidic analytes resulting in the higher retention. Common acids used for mobile 
phase preparations are phosphoric acid, formic acid and acetic acid. Low pH also 
minimises the interaction of basic analytes with surface silanols on the silica 
packing (because silanols do not ionize at acidic pH). Also, the lifetime of most 
silica-based columns is excellent in the pH range of 2–8. However, basic analytes 
are ionized at low pH and might not be retained unless ion – pairing reagents are 
used.  
d. Ion – pairing reagents 
 Ion – pairing reagents are detergents like molecules added to the mobile 
phase to provide additional retention or selectivity for the analytes with opposite 
charge. Long- alkyl sulphonates are commonly used for the separation of water 
soluble basic analytes in the analysis of water soluble vitamins. Amine modifiers 
such as trimethylamine are often used in the mobile phase to reduce peak tailing 
caused by strong interaction of basic analytes with acidic surface silanols. For 
acidic analytes, ion pairing reagents such as tetra – alkyl ammonium salts are 
often used.  
 
e. Isocratic vs gradient analysis  
Traditionally, most pharmaceutical assays are isocratic analysis employing 
the same mobile phases throughout the elution of the sample. Isocratic analyses 
are particularly common in quality control applications since they use simpler 
HPLC equipment and premixed mobile phases. 
 In contrast, gradient analysis in which the strength of the mobile phase is 
increased with time during sample elution, is suited for complex samples and 
those containing analytes of wide polarities. Gradient chromatography is 
amenable for high – through put screening applications and for impurity testing. It 
yields better seperation for early peaks and sharper peaks for late eluters. 
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IV. VALIDATION PARAMETERS AS PER ICH GUIDELINES8 
a. Specificity 
 Specificity is the ability to assess unequivocally the analyte in presence of 
components which may be expected to be present like impurities, matrix etc. An 
investigation of specificity should be conducted during the validation of 
identification tests, the determination of impurities and the assay. The procedures 
used to demonstrate specificity will depend on the intended objective of the 
analytical procedure.  
b. Accuracy 
The accuracy of an analytical procedure expresses the closeness of 
agreement between the value which is accepted either as convential true value or 
an accepted reference value and the value found. Accuracy should be established 
across the specified range of the analytical procedure. 
 Assay  
1) Drug substance 
2) Drug product 
 Impurities (Quantitation) 
 Accuracy should be assessed using a minimum of 9 determinations over a 
minimum of 3 concentration levels covering the specified range (e.g., 3 
concentrations/3 replicates each of the total analytical procedure). Accuracy 
should be reported as percent recovery by the assay of known added amount of 
analyte in the sample or as the difference between the mean and the accepted true 
value together with the confidence intervals. 
c. Precision 
 The precision of an analytical procedure expresses the closeness of 
agreement (degree of scatter) between a series of measurements obtained from 
multiple sampling of the same homogeneous sample under the prescribed 
conditions. Precision may be considered at three levels:  repeatability, 
intermediate precision and reproducibility. 
Acceptance criteria: %RSD  2 
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i. Repeatability (Intra assay precision) 
 Repeatability expresses the precision under the same operating conditions 
 over a short interval of time.  
 
ii. Intermediate precision  
 Intermediate precision expresses within-laboratories variations: different 
 days, different analysts, different equipment, etc. 
 
iii. Reproducibility  
 Reproducibility expresses the precision between laboratories (collaborative 
 studies, usually applied to standardization of methodology). 
 
d. Limit of detection (LOD) 
 LOD is defined as the smallest concentration of an analyte detected, but 
not necessarily quantified. A few approaches to determine LOD are listed below 
i. Based on signal-to-noise approach 
A signal-to-noise ratio between 3 or 2:1 is generally considered acceptable 
 for estimating the detection limit.  
ii. Based on the standard deviation of the response and the slope  
 The detection limit (DL) may be expressed as: 
DL = 3.3 σ / S 
Where         
          σ = the standard deviation of the response 
S = the slope of the calibration curve 
e. Limit of quantification (LOQ) 
 LOQ is defined as the lowest concentration of an analyte determined with 
acceptable precision, accuracy and reliability by a given method under stated 
experimental conditions. A few approaches to determine LOQ are listed below 
 
Introduction  
 
 
 
Department of Pharmaceutical Analysis  17 
i. Based on signal-to-noise approach  
A signal-to-noise ratio of 10: 1 is generally considered  acceptable for 
 estimating the quantitation limit. 
ii. Based on the standard deviation of the response and the slope  
 The quantitation limit (QL) may be expressed as: 
Quantitation limit, QL = 10 σ / S 
 Where  
          σ = the standard deviation of the response 
          S = the slope of calibration curve 
f. Linearity 
The linearity of an analytical procedure is its ability (within a given range) 
to obtain test results which are directly proportional to the concentration (amount) 
of analyte in the sample. This relationship is evaluated by statistical methods. For 
the establishment of linearity, a minimum of five concentrations is recommended. 
The parameters to be calculated are correlation coefficient, y-intercept, slope and 
residual sum of squares. 
g. Range 
The range of an analytical procedure is the interval between the upper and 
lower concentration (amounts) of analyte in the sample (including these 
concentrations) for which it has been demonstrated that the analytical procedure 
has a suitable level of precision, accuracy and linearity.  
h. Robustness 
The robustness of an analytical procedure is a measure of its capacity to 
remain unaffected by small, but deliberate variations in method parameters and 
provides an indication of its reliability during normal usage. 
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2.  LITERATURE REVIEW9-12 
 
 Madhukar A. et al. reported a validated HPLC method for analysis of 
metformin hydrochloride.         
 Prasad PBN. et al. proposed a RP – HPLC method for simultaneous 
determination of metformin and saxagliptin in formulation.          
 Sohan SC. et al. reported validated RP - HPLC and derivative spectroscopy 
methods for determination of teneligliptin. 
 Ganesh K. et al. reported RP – HPLC and UPLC tandem mass 
spectroscopy methods for stability studies and identification of degradation 
products of teneligliptin. 
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3. DRUG PROFILE13-15 
Drug name                           :    Metformin  
Drug structure                      :     
 
 
 
 
                                           
IUPAC name :   N, N – dimethylimidodicarbonimidic 
diamide 
Molecular formula :  C4 H11 N5 
Molecular weight  :  165.62 
Description :  White, crystalline, hygroscopic  
Solubility  :  Freely soluble in water; 
   Slightly soluble in ethanol (95%) 
Category  :  Type II diabetes mellitus 
Strength :  500 mg 
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Drug name                           :    Teneligliptin 
Drug structure                      : 
 
                                                     
 
 
 
IUPAC name :  {(2S, 4S)- 4- [ 4- (3- methyl -1- phenyl - 1H 
– pyrazol - 5 yl) - 1- piperazinyl] - 2 – 
pyrolindinyl} (1,3- thiazolindin - 3- yl ) 
methanone 
Molecular formula :  C22 H30 N6 OS 
Molecular weight  : 426.58 
Description : White powder 
Solubility  : Soluble in methanol and water 
Category  : Type II diabetes mellitus 
Strength : 20 mg 
 
Aim & Plan of Work 
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4. AIM AND PLAN OF WORK 
 
Diabetes is a chronic, metabolic disease characterized by elevated levels of 
blood glucose (or blood sugar), which leads over time to serious damage to heart, 
blood vessels, eyes, kidneys and nerves. The most common is type 2 diabetes, 
usually in adults, which occurs when the body becomes resistant to insulin or 
doesn’t make enough insulin. According to WHO, around 422 million adults have 
diabetes and 1.5 million deaths are directly attributed to diabetes each year.16 
Antidiabetic drugs can be used alone or in combination for the 
management of diabetes. Metformin is an oral anti-hyperglycaemic drug 
belonging to the class of biguanides which is used in the management of  
type 2 diabetes.17 Teneligliptin is a third generation dipeptidyl peptidase-4 
inhibitor   approved for treatment of    type 2 diabetes. Combination of these drugs 
has been recently launched and it has been reported that teneligliptin co-
administered with metformin produced significant reductions in HbA1c in patients 
with type 2 diabetes mellitus without increasing the risk of hypoglycemia.18 No 
HPTLC and HPLC methods have been reported for the simultaneous analysis of  
these drugs in combined dosage form. Hence, an attempt is made to                                   
develop HPTLC and HPLC methods for the simultaneous determination of 
metformin and teneligliptin in tablet dosage form. 
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5. MATERIALS AND INSTRUMENTS 
Active pharmaceutical ingredient (API) 
Metformin and Teneligliptin were procured from Tristar Formulations  
Pvt. Ltd., Pondicherry, India and Zydus Cadila Healthcare Pvt. Ltd., Gujarat, India 
respectively.  
 
Formulation 
ZITA – MET PLUS 20mg/ 500mg extended release tablets: Glenmark 
Pharmaceuticals.      
 Chemicals and solvents used 
 
 Water- HPLC grade 
 Methanol HPLC grade, AR grade  
 Tetrahydrofuran - HPLC grade 
 Formic acid- AR grade 
 Chloroform- LR grade 
 Sodium hydroxide- LR grade 
 Hydrochloric acid- AR grade 
 Hydrogen peroxide- LR grade 
 Ammonia 25% solution 
 Ammonium acetate 
 Potassium dihydrogen phosphate 
 Ortho  Phosphoric acid 
 Hydrochloric acid (0.5 N) 
 Sodium hydroxide (0.5 N) 
 30% hydrogen peroxide  
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All the above chemicals and solvents were supplied by S.D. Fine 
Chemicals Pvt. Ltd., India, Sigma - Aldrich Chemicals Pvt. Ltd., Maharashtra, 
India and Ranbaxy chemicals Pvt. Ltd., New Delhi, India. 
 
Stationary phases used 
 Pre-coated silica gel 60F254 on aluminium sheets were procured from 
 Merck, Germany. 
 Hibar, C18 (250mm X 4.0mm, 5μm) column was obtained from Merck Pvt. 
 Ltd., Mumbai. 
 
Instruments used 
 Shimadzu digital electronics balance 
 Elico Pvt. Limited, India, pH meter 
 Jasco V-600 UV/ Vis- spectrophotometer 
 Camag HPTLC system (with TLC Scanner-3, Win CATS software and 
Linomat V as application device) 
 Shimadzu HPLC Prominence i LC – 2030 liquid chromatograph system 
with UV – VISIBLE detector and auto sampler injector. Chromatograms 
were recorded and integrated on PC installed with Lab solutions 
chromatographic software. 
 Shimadzu liquid chromatograph equipped with LC – 10 AT VP pump, 
SPD-M10A VP diode array detector and rheodyne 7725 i injected with a 
20 l loop. Chromatograms were recorded and integrated on PC installed 
with LC solutions chromatographic software. 
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6. EXPERIMENTAL SECTION 
I. DEVELOPMENT AND VALIDATION OF HPTLC METHOD 
FOR THE SIMULTANEOUS DETERMINATION OF 
METFORMIN AND TENELIGLIPTIN IN  
TABLET DOSAGE FORM 
1. Selection of plate 
 Pre-coated silica gel 60F254 on aluminium sheet was selected for the study. 
2.  Selection of solvent
 
Ideal properties of a solvent employed for HPTLC are 
a) Drug should be soluble in the solvent used 
b) Drug should show stability in the solvent used 
c) Solvent should be volatile 
Accordingly, methanol was selected as the solvent. 
3.  Selection of wavelength 
 UV spectra of metformin and teneligliptin were recorded on pre-coated 
TLC plate. The Ȝmax of metformin and teneligliptin were found to be 237 nm and 
258 nm respectively. From the overlain UV spectra of the drugs, a wavelength of 
258 nm was selected for the study, fig. 1. 
Fig. 1: Overlain UV spectra of metformin and teneligliptin  
on precoated TLC plate 
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4. Developing optimum mobile phase system 
A solvent system should be selected in such a way that it would give 
compact spots and good separation from solvent front and application position. 
Initially, different solvent systems were tried and observations were as given in 
table 1. 
Table: 1 Selection of mobile phase system 
SOLVENT SYSTEMS USED OBSERVATIONS 
Chloroform: Methanol: Ammonia 
[1:9:0.1, v/v/v] Very low Rf value for metformin (0.06)
 
Chloroform: Methanol: Water 
[1:9:0.5, v/v/v] Teneligliptin moved with solvent front  
Ethyl acetate: Methanol: Water: 
Formic acid [5:3:0.7:1, v/v/v] Metformin moved with solvent front 
Methanol: Tetrahydrofuran: 
Ammonia [7:3:0.1, v/v/v] Compact spots with good separation 
   
 Among these systems, methanol: tetrahydrofuran: ammonia was selected 
because this system gave good separation with compact spots. 
5. Optimization of mobile phase ratio 
 Different ratios of methanol: tetrahydrofuran: ammonia like 6.5: 2.5: 0.1, 
6.5: 2.5: 0.2, 6.5: 2.5: 0.5 and 7: 3: 0.1, v/v/v etc. were tried, from which the ratio 
of (7: 3: 0.1, v/v/v) was selected because it gave compact spots with good 
separation from solvent front and application positions. 
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6. Fixed experimental conditions 
 
Sorbent layer :   Silica gel 60F254 
Mobile phase :   Methanol: Tetrahydrofuran: Ammonia [7:3:0.1, v/v/v]   
Saturation time : 15 minutes 
Total run distance : 8 cm 
Slit dimension :     5 x 0.45 mm  
Plate thickness :     250 ȝm 
Light source :     Deuterium lamp 
Detection wavelength  :     258 nm 
Rf values   :     Metformin 0.29 ± 0.02 
          Teneligliptin 0.71 ± 0.02 
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 VALIDATION OF THE METHOD  
  
The validation of the developed method was carried out for various 
parameters like limit of detection (LOD), limit of quantification (LOQ), linearity, 
accuracy, precision and specificity. 
 
1. Limit of detection [LOD] & Limit of quantification [LOQ] 
The LOD and LOQ values were determined by injecting lower 
concentrations of the drugs. The LOD values for metformin and teneligliptin were 
found to be 0.01 and 0.1g/band respectively and their LOQ values were found to 
be 0.07 and 0.4g/band respectively, fig. 2-5. 
   
Fig. 2: Limit of detection – Metformin 
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Fig. 3: Limit of detection – Teneligliptin 
 
Fig. 4: Limit of quantification – Metformin  
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Fig. 5: Limit of quantification – Teneligliptin 
 
2. Linearity  
a) Metformin 
Metformin was found to be linear in the concentration range of 6.25-17.5 
g/band. Calibration curve was plotted using concentration (x) versus peak area 
(y). The slope, intercept and correlation coefficient values were found to be 
1132.521, 6055.128 and 0.9991 respectively, fig. 6; table 2. 
The regression equation is as follows 
  Peak area = 6055.128 + 1132.521 x concentration  
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Fig. 6: Calibration graph of metformin 
 
 
Table 2: Calibration data (6.25 – 17.50 µg/band) 
Concentration (µg/band) Peak Area 
6.25 13296.8 
7.5 14965.5 
8.75 16384.9 
10.00 17390.0 
11.25 19311.4 
12.50 20268.3 
13.75 21735.8 
15.00 23118.7 
16.25 24468.4 
17.5 25306.2 
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b) Teneligliptin 
Teneligliptin was found to be linear in the concentration range of 0.25-0.7 
g/band. Calibration curve was plotted using concentration (x) versus peak area 
(y). The slope, intercept and correlation coefficient values were found to be 2.725, 
-125.859 and 0.9981 respectively, fig. 7; table 3. 
 
The regression equation is as follows 
 
  Peak area = (-125.859) + 2.725x concentration  
 
Fig. 7: Calibration graph of teneligliptin 
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Table 3: Calibration data (0.25 – 7 µg/band) 
Concentration (µg/band) Peak Area 
0.25 624.7 
0.30 745.4 
0.35 881.3 
0.40 993.5 
0.45 1188.9 
0.50 1278.4 
0.55 1449.0 
0.60 1606.3 
0.65 1722.1 
0.70 1891.7 
 
3. Accuracy 
 Recovery studies were done for determining accuracy parameter. It was 
done by mixing known quantity of standard drug with the analysed sample 
formulation and the contents were reanalysed by the proposed method. Recovery 
studies were carried out at 80, 100 and 120% levels. The percentage recovery and 
its %RSD were calculated, table 4 and 5. 
Table 4: Recovery studies for metformin 
Level %Recovery %RSD* 
80% 99.62 0.6 
100% 101.25 0.37 
120% 100.92 0.54 
*RSD of 6 observations 
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Table 5: Recovery studies for teneligliptin 
Level %Recovery %RSD* 
80% 99.99 0.19 
100% 100.98 0.64 
120% 101.06 0.64 
*RSD of 6 observations 
 
4.   Precision  
Precision of method was demonstrated by: 
i.) Intra-day precision 
ii.)  Inter-day precision 
iii.)  Repeatability 
a) Repeatability of sample application 
b) Repeatability of sample measurement 
 
i) Intraday precision  
Intraday precision was studied by carrying out the analysis of the standard 
drugs at two different concentrations in the linearity range of the drugs for three 
times on the same day and %RSD was calculated, table 6.   
Table 6: Intraday precision 
Concentration 
 
Peak Area % RSD 
Metformin Teneligliptin Metformin Teneligliptin 
10.00(µg/band) 
Metformin 
0.4(µg/band) 
Teneligliptin 
17505.5 969.3 
0.11 0.43 17491.6 950.5 
17467.2 944.8 
12.50(µg/band)  
Metformin 
0.5(µg/band) 
Teneligliptin 
19864.2 1171.0 
1.3 1.7 19692.6 1130.9 
19796.0 1157.5 
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ii) Inter-day precision  
Inter-day precision was studied by carrying out the analysis of the standard 
drugs at two different concentrations in the linearity range of the drugs for three 
days over a period of one week and % RSD was calculated, table 7.    
Table 7: Inter-day precision 
Concentration Peak Area % RSD Metformin Teneligliptin Metformin Teneligliptin 
10.00(µg/band) 
Metformin 
0.4(µg/band) 
Teneligliptin 
17593.2 983.3 
0.54 1.26 17467.2 958.8 
17406.0 973.1 
12.50(µg/band) 
Metformin 
0.5(µg/band) 
Teneligliptin 
19973.1 1195.0 
0.44 1.43 19796.0 1157.5 
19872.8 1198.5 
 
iii) Repeatability 
a)  Repeatability of sample application 
            Repeatability of sample application was evaluated by spotting drug 
solution six times on pre-coated TLC plate.  Plate was then developed, scanned 
and %RSD was calculated, table 8.   
 
Table 8: Repeatability of sample application 
Concentration 
Peak Area % RSD 
Metformin Teneligliptin Metformin Teneligliptin 
10.00(µg/band) 
Metformin 
0.4(µg/band) 
Teneligliptin 
17988.3 956.2 
0.13 0.7 
17982.8 974.6 
17927.0 963.6 
17960.1 959.5 
17941.8 956.8 
17960.3 960.3 
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b) Repeatability of sample measurement  
   Repeatability of measurement of peak area was evaluated by spotting the 
standard drug solutions on pre-coated TLC plate. After development of the plate 
the separated spots were scanned six times without changing the position of the 
plate and % RSD was calculated, table 9.   
Table 9: Repeatability of sample measurement 
Concentration 
Peak Area % RSD 
Metformin Teneligliptin Metformin Teneligliptin 
 
10.00(µg/band) 
Metformin 
0.4(µg/band) 
Teneligliptin 
17799.0 986.9 
0.22 1.37 
17709.8 988.1 
17770.9 994.3 
17755.3 969.9 
17696.7 959.2 
17771.3 988.1 
 
5. Specificity 
 The peak purity of metformin and teneligliptin was assessed by comparing 
their respective spectra at peak start, peak apex and peak end positions of the spot. 
The good correlation among spectra acquired at start (s), apex (m) and end (e) of 
the peaks metformin[{correlation r(s,m)=0.99943}, r(m,e)=0.99908}] and 
teneligliptin [{correlation r(s,m) =0.99966}, r(m,e) =0.99521}]  indicates good 
peak purities of drugs, fig. 8 and 9. It can be concluded that no impurities or 
degradation products migrated with the peaks obtained from standard solutions of 
the drugs. 
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Fig. 8: Peak purity graph showing correlation between peak maxima and 
slope for metformin 
 
Fig. 9: Peak purity graph showing correlation between peak maxima and 
slope for teneligliptin 
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ANALYSIS OF FORMULATION 
1. Preparation of stock solution 
 A stock solution of metformin (2500 µg/ml) and teneligliptin (100 µg/ml) 
was prepared in methanol. 
2. Preparation of sample solutions  
 Ten tablets each containing 500 mg of metformin and 20 mg of 
teneligliptin were weighed and the average weight was determined. Amount of 
powder equivalent to 125 mg of metformin and 5 mg of teneligliptin was 
transferred to a 50 ml volumetric flask, and 25 ml methanol was added. The 
contents of the flask were shaken for 10 minutes, followed by dilution to volume 
with methanol to provide a solution containing 2500 µg/ml of metformin and 100 
µg/ml of teneligliptin. This solution was filtered through a 0.45 mm membrane 
filter before injection.  
3. Recording the chromatograms 
 With the fixed chromatographic conditions, 2.5 – 7 ȝl (i.e. 6.25 to 17.5 
ȝg/band for metformin and 0.25 to 0.7 ȝg/band for teneligliptin) from standard 
stock solution and suitable volumes from sample solution were applied on the 
precoated TLC plate. The plates were analysed and chromatograms were  
recorded and results are given in table 10. The standard chromatograms, overlain 
UV spectra of drugs in formulation and 3D image of standard chromatograms are 
given in  fig. 10 – 21. 
Table 10: Analysis of formulation 
Drug 
Amount of drug 
(mg/tablet) % Label 
claim %RSD* Labelled Found 
Zita met plus  (Teneligliptin  
20 mg &  Metformin 500mg) 
20 mg 19.84 mg 99.2 0.98 
500 mg 491.4 mg 99.3 1.12 
*RSD of 6 observations 
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CHROMATOGRAMS OF STANDARDS 
Fig. 10: Chromatogram of standard 1 (MET 6.25 ȝg/band; TENE 0.25 ȝg/band) 
  
Fig. 11: Chromatogram of standard 2 (MET 7.5 ȝg/band; TENE 0.3 ȝg/band) 
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Fig. 12: Chromatogram of standard 3 (MET 8.75 ȝg/band; TENE 0.35 ȝg/band) 
 
Fig. 13: Chromatogram of standard 4 (MET 10.00 ȝg/band; TENE 0.4 ȝg/band) 
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Fig. 14: Chromatogram of standard 5 (MET 11.25ȝg/band; TENE 0.45ȝg/band) 
 
Fig. 15: Chromatogram of standard 6 (MET 12.5 ȝg/band; TENE 0.5 ȝg/band) 
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Fig. 16: Chromatogram of standard 7 (MET 13.75ȝg/band; TENE0.55ȝg/band) 
 
Fig. 17: Chromatogram of standard 8 (MET 15.00ȝg/band; TENE 0.6 ȝg/band) 
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Fig. 18: Chromatogram of standard 9 (MET 16.25ȝg/band; TENE0.65ȝg/band) 
 
Fig. 19:  Chromatogram of standard 10 (MET 17.5ȝg/band; TENE 0.7ȝg/band) 
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Fig. 20: Overlain UV spectra of drugs in formulation on  
precoated TLC plate 
 
Fig. 21: 3D Image of standard chromatograms
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II. DEVELOPMENT OF VALIDATED RP-HPLC METHOD 
FOR THE SIMULTANEOUS DETERMINATION OF 
 METFORMIN AND TENELIGLIPTIN IN TABLET  
DOSAGE FORM 
1. Selection of stationary phase 
 Since metformin and teneligliptin are polar in nature, RP-HPLC method 
with C18 column was selected for method development. 
2. Selection of wavelength 
 Selectivity of HPLC method that uses UV detector depends on proper 
selection of wavelength. A wavelength which gives good response for the drugs to 
be detected is to be selected. From UV spectral studies, 247 nm was selected as 
detection wavelength for metformin and teneligliptin, fig. 22.  
Fig. 22: Overlain UV spectra of metformin and teneligliptin 
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3. Selection of mobile phase  
 Solvent type, solvent strength, strength of buffer and optimum pH were 
optimised to get the chromatographic conditions that gave best separation, fig. 23-
30; table 11. 
Table 11: Selection of mobile phase 
Figure 
No. 
Mobile 
phase 
Chromatograms 
Metformin Teneligliptin 
23 & 24 
Water: 
Methanol 
 
 
 
 
 
 
Asymmetric peak 
 
 
 
 
 
 
Peak tailing 
25 & 26 
10 mM 
Sodium 
dihydrogen 
Ortho 
phosphate: 
Methanol 
 
 
 Peak tailing 
 
 Broad peak 
27 & 28 
 
 
10 mM 
Potassium 
dihydrogen 
Ortho 
phosphate: 
Methanol 
 
 
 
 
 
 
 
 
Peak shape good 
 
 
 
 
 
 
Good symmetrical peak 
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Figure 
No. 
Mobile 
phase 
Chromatograms 
Metformin Teneligliptin 
29 & 30 
 
 
10 mM 
Ammonium 
acetate: 
Methanol 
 
 
 
 
 
 
 
 
Peak tailing 
 
 
 
 
 
 
 
 Peak tailing 
 
4. Selection of mobile phase ratio 
           Mobile phase system containing 10 mM potassium dihydrogen ortho 
phosphate and methanol was tested in different ratios like 30: 70, 35: 65 and  
40: 60 v/v. A ratio of 35: 65% v/v gave good resolution and peak characteristics, 
fig. 31-33; table 12. 
Table 12: Selection of mobile phase ratio 
Figure  
No. 
Mobile 
phase ratio Chromatogram Observation 
31 
 
30:70 
 
 
 
 
 
 
 
 
 
Less 
resolution 
between the 
drug peaks 
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Figure  
No. 
Mobile 
phase ratio Chromatogram Observation 
32 
 
35: 65 
 
 
 
 
 
 
 
 
Good peak 
shape and 
acceptable 
resolution 
33 
 
 
40: 60 
 
 
 
 
 
 
 
 
 
Drug peak 
shapes not 
good 
 
5. Selection of pH 
           Different pH’s of 10 mM potassium dihydrogen orthophosphate such as  
3, 3.5, 4, 4.5 and 5.4 were tried. Good peak characteristics was observed for pH 4 
and hence selected for further studies, fig. 34–38; table 13.  
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Table 13: Selection of pH 
Figure 
No. pH  Chromatogram Observation 
34 3.0 
 
 
 
 
 
 
Split peak 
obtained for 
metformin 
35 3.5 
 
Peak 
asymmetry 
for 
metformin 
36 4.0 
 
Good peak 
shapes 
37 4.5 
 
Asymmetric 
peak shape 
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Figure 
No. pH  Chromatogram Observation 
38 5.4 
 
Less 
resolution 
between the 
drug peaks 
 
6. Fixed chromatographic conditions 
Stationary phase :   Hibar, C18 column (250mm X 4.0mm, 5m)                                                                
Mobile phase            :   10 mM potassium dihydrogen orthophosphate                            
(adjusted to pH 4 using ortho phosphoric acid): 
Methanol                 
Solvent ratio :    35: 65, v/v 
Flow rate :    1.0 ml/min 
Detection wavelength  : 247 nm 
Temperature  :   Room temperature 
 A chromatogram showing the separation of metformin and teneligliptin 
using the fixed chromatographic conditions is shown in fig. 39. 
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Fig. 39:  A chromatogram of metformin and teneligliptin using fixed 
chromatographic conditions 
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METHOD VALIDATION  
 The validation of the developed method was carried out for various 
parameters like linearity, accuracy, precision, limit of detection (LOD), limit of 
quantification (LOQ), stability, robustness and specificity. 
1. Limit of detection and limit of quantification (LOD & LOQ) 
 
 The LOD and LOQ values were determined by injecting lower 
concentrations of the drugs. The LOD values for metformin and teneligliptin were 
found to be 5 and 10 ng/ml respectively and their LOQ values were found to be 10 
and 70 ng/ml respectively, fig. 40-43 
 
Fig. 40: LOD - Metformin 
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Fig. 41: LOD - Teneligliptin 
 
Fig. 42: LOQ – Metformin 
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Fig. 43: LOQ – Teneligliptin 
 
2. Linearity 
a) Metformin 
Metformin was found to be linear in the concentration range of 25 – 250 
µg/ml. Calibration curve was plotted using concentration (x) versus peak area (y). 
The slope, intercept and correlation coefficient values were found to be 46749.2, 
281930 and 0.9998 respectively, fig. 44; table 14. 
The regression equation is as follows 
 Peak area = 281930 + 46749.2 x concentration  
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Fig. 44: Calibration graph – Metformin 
 
Table 14:  Metformin - Calibration data (25 – 250 µg/ml) 
Concentration (µg/ml) Peak Area 
25 1354287 
50 2611634 
75 3796175 
100 4972965 
125 6188947 
150 7408120 
175 8428047 
200 9700838 
225 10771794 
250 11866670 
0
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4000000
6000000
8000000
10000000
12000000
14000000
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b) Teneligliptin 
Teneligliptin was found to be linear in the concentration range of 1 – 10 
µg/ml. Calibration curve was plotted using concentration (x) versus peak area (y). 
The slope, intercept and correlation coefficient values were found to be 16392.2,   
-1954.47 and 0.9991 respectively, fig. 45; table 15.  
The regression equation is as follows 
 Peak area = (-1954.47) + 16392.2 x concentration  
Fig. 45: Calibration graph - Teneligliptin 
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Table 15: Teneligliptin - Calibration data (1 – 10 µg/ml) 
Concentration (µg/ml) Peak Area 
1 15169 
2 29070 
3 46856 
4 62792 
5 79957 
6 98550 
7 112943 
8 131102 
9 147915 
10 157651 
 
3. Accuracy  
 Recovery studies were done for determining accuracy parameter. It was 
done by spiking known quantity of standard drug with the analysed sample 
formulation and the contents were reanalysed by the proposed method. Recovery 
studies were carried out at 80, 100 and 120% levels. The percentage recovery and 
its %RSD were calculated, table 16 & 17. 
Table 16: Recovery studies for metformin 
Level %Recovery %RSD* 
80% 99.9 0.71 
100% 99.78 0.77 
120% 103.81 0.77 
*RSD of 6 observations 
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Table 17: Recovery studies for teneligliptin 
Level %Recovery %RSD* 
80% 99.43 0.7 
100% 100.27 0.57 
120% 99.66 0.81 
*RSD of 6 observations 
 
4. Precision 
 Precision of method was demonstrated by: 
i.) Intraday precision 
ii.)  Inter-day precision 
iii.)  Repeatability 
a. Repeatability of injection 
 
i) Intraday precision  
Intra-day precision was studied by carrying out the analysis of the standard 
drugs at two different concentrations in the linearity range of the drugs for three 
times on the same day and %RSD was calculated, table 18. 
Table 18: Intraday precision 
Concentration 
Peak Area %RSD 
Metformin Teneligliptin Metformin Teneligliptin 
100 (µg/ml) 
Metformin 
4 (µg/ml) 
Teneligliptin 
5123139 60866 
0.88 0.46 5173112 61212 
5214763 61427 
125 (µg/ml) 
metformin 
5 (µg/ml) 
Teneligliptin 
6299618 78644 
0.98 0.29 6279424 79109 
6184767 78945 
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ii) Inter-day precision   
Inter-day precision was studied by carrying out the analysis of the standard 
drugs at two different concentrations in the linearity range of the drugs for three 
days over a period of one week and %RSD was calculated, table 19. 
Table 19: Inter-day precision 
 
 Concentration Peak Area % RSD 
Metformin Teneligliptin Metformin Teneligliptin 
100 (µg/ml) 
Metformin 
4 (µg/ml) 
Teneligliptin 
5172965 62792 
0.65 0.19 4967626 62553 
5027176 62720 
125 (µg/ml) 
Metformin 
5 (µg/ml) 
Teneligliptin 
6188947 79957 
0.71 1.15 6203468 79833 
6271502 78311 
 
iii) Repeatability 
 
a) Repeatability of injection 
Standard drug solution was injected six times and its %RSD was 
calculated, table 20. 
Table 20: Repeatability of injection 
Concentration 
Peak Area %RSD 
Metformin Teneligliptin Metformin Teneligliptin 
125 (µg/ml) 
Metformin 
5 (µg/ml) 
Teneligliptin 
6278397 79627 
0.09 0.43 
6276164 79874 
6279061 78968 
6279365 79738 
6266020 79736 
6268003 79864 
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5.  Stability  
 The standard drug solutions were subjected to stability studies under room 
temperature and refrigerated conditions. Stability of solutions were analysed by 
looking for any changes in retention time, resolution, peak shape etc. The drug 
solutions were found to be stable for 5 hours at room temperature and 24 hours at 
refrigerated conditions, fig. 46 and 47. 
Fig. 46: Stability of the analyte at room temperature  
 
Experimental Section 
 
 
 
Department of Pharmaceutical Analysis  60 
 
 
Fig. 47: Stability of the analyte at refrigerator 
 
6. Robustness  
The concept of robustness of an analytical procedure has been defined by 
the ICH as a measure of its capacity to remain unaffected by small, but deliberate 
variations in method parameters. Important parameters in the method were 
systemically varied and their effect on separation was measured as follows:- 
 
 ± 0.1 units of flow rate (fig. 48) 
 ± 2 units of mobile phase ratio (fig. 49) 
 ± 0.5 units of pH (fig. 50) 
 
 
 
Experimental Section 
 
 
 
Department of Pharmaceutical Analysis  61 
 
 
Fig. 48: Effect of flow rate 
 
Fig. 49: Effect of mobile phase ratio
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Fig. 50: Effect of pH 
 
7. Specificity (forced degradation studies) 
 Sample degradation is also a technique for assessing specificity by 
deliberately degrading the sample and to look for the appearance of other peaks in 
the chromatogram. Here, the drugs were subjected to acid degradation  
(0.5 N HCL), base degradation (0.5 N NaOH), oxidative degradation (3% H2O2) 
and neutral conditions to achieve 10 to 20% degradation from the initial material. 
Procedure 
 The stress testing was conducted as per ICH guidelines. 
 Forced degradation for the drugs were carried out under acid hydrolysis, 
base hydrolysis, oxidative stress conditions and neutral conditions. 
 Drug at concentration 1 mg/ml was used in all degradation studies. 
 In each study, blank and control (zero hour sample) were used to compare 
and calculate the % degradation. 
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There were four samples prepared in each stress test 
1. Blank solution stored under normal condition 
2. Blank solution subjected to stress like the drug 
3. Zero time sample containing the drug which is stored under normal 
condition (control) and 
4. Drug solution subjected to stress 
i. Hydrolytic studies 
a. Acidic condition  
 The solution was prepared by dissolving the drugs in methanol and the 
drugs were subjected to accelerated degradation under acidic condition with 
0.5 N HCL and the sampling was done at every 15 minutes till sufficient 
degradation was achieved, fig. 51 – 53. 
Fig. 51: Chromatogram of drug solution in acidic condition 
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Fig. 52: Peak purity view of metformin  
 
Fig. 53: Peak purity view of teneligliptin 
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 b. Alkaline condition 
 The drugs were dissolved in methanol and the drug was subjected to 
accelerated degradation under alkaline condition with 0.5 N NaOH and the 
sampling was done at every 15 minutes till sufficient degradation was 
achieved. The resulting solution was neutralized, appropriately diluted and 
chromatograms were recorded, fig. 54 – 56. 
 
Fig. 54: Chromatogram of drug solution in alkaline condition  
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Fig. 55: Peak purity view of metformin 
 
Fig. 56: Peak purity view of teneligliptin 
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c. Oxidative studies 
 Oxidation studies were performed in 3% H2O2 at room temperature. The 
resulting solution was appropriately diluted and chromatograms were 
recorded, fig. 57 – 59. 
Fig. 57: Chromatogram of drug solution in oxidative condition  
 
Fig. 58: Peak purity view of metformin 
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Fig. 59: Peak purity view of teneligliptin 
 
 
d. Neutral condition  
 
The drugs were dissolved in methanol and the solution was stored at room 
temperature and analysed periodically, fig. 60 – 62.  
 
Fig. 60: Chromatogram of drug solution in neutral condition  
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Fig. 61: Peak purity view of metformin 
 
Fig. 62: Peak purity view of teneligliptin 
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 In all degradation studies, there was no corresponding formation of 
degradation products except oxidation studies when compared to the standard 
solution of the drug. Photo diode array detection was used as an evidence of the 
specificity of the method and to evaluate the homogeneity of the drug peak. 
Chromatographic peak purity data was obtained from the spectral analysis report 
and peak purity index values close to 1 indicates homogenous peaks thus 
establishing the specificity of the assay method.  
8. System suitability parameters 
The USP defines parameters that can be used to determine system 
suitability prior to analysis. These parameters include plate number (N), tailing 
factor (Tf), capacity factor (k`), resolution (Rs) and relative standard deviation of 
peak area for repetitive injections, table 21. 
Table 21: System suitability studies 
Drug name 
Number of 
theoretical 
plates 
(N) 
Tailing 
Factor 
(Tf) 
Capacity 
factor 
(k`) 
Resolution 
(Rs) 
Relative 
standard 
deviation 
of peak 
area 
(%RSD) 
METFORMIN 1652 1.3 
0.657 4.746 
0.09 
TENELIGLIPTIN 1381 1.5 0.43 
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ANALYSIS OF FORMULATION 
1. Preparation of stock solution  
 A stock solution of metformin (2500 µg/ml) and teneligliptin (100 µg/ml) 
was prepared in methanol. 
2. Preparation of sample solution  
 Ten tablets each containing 500 mg of metformin and 20 mg of 
teneligliptin were taken for the studies and the average weight was determined. 
Amount of powder equivalent to 125 mg of metformin and 5 mg of teneligliptin 
was taken and transferred to a 50 ml volumetric flask, and 25 ml methanol was 
added. The contents of the flask were shaken for 10 minutes, followed by dilution 
to volume with methanol to provide a solution containing 2500 µg/ml of 
metformin and 100 µg/ml of teneligliptin. This solution was filtered through a 
0.45 mm membrane filter before injection. 
 
3. Recording the chromatogram 
 A steady baseline was recorded with the fixed chromatographic conditions 
and 20 L of standard drug solutions and sample solutions were injected and 
chromatograms were recorded, fig. 63-72. Calibration curve was plotted using the 
standard drug peak area versus concentration of standard solutions. The results of 
formulation analysis are given in, table 22. 
 
Table 22: Analysis of formulation 
Drug 
Amount of drug 
(mg/tablet) % Label 
claim 
%RSD* 
Labelled Found 
Zita met plus  (Teneligliptin  
20 mg  & Metformin 500mg) 
20 mg 19.71 mg 98.55 1.42 
500 mg 483.33 mg 96.66 1.14 
*RSD of 6 observations 
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STANDARD CHROMATOGRAMS 
Fig. 63: Chromatogram of standard 1 (MET 25μg/ml; TENE 1 μg/ml) 
 
Fig. 64: Chromatogram of standard 2 (MET 50μg/ml; TENE 2 μg/ml) 
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Fig. 65: Chromatogram of standard 3 (MET 75μg/ml; TENE 3 μg/ml) 
 
Fig. 66: Chromatogram of standard 4 (MET 100μg/ml; TENE 4 μg/ml) 
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Fig. 67: Chromatogram of standard 5 (MET 125μg/ml; TENE 5 μg/ml) 
 
Fig. 68: Chromatogram of standard 6 (MET 150μg/ml; TENE 6 μg/ml) 
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Fig. 69: Chromatogram of standard 7 (MET 175μg/ml; TENE 7 μg/ml) 
 
Fig. 70: Chromatogram of standard 8 (MET 200μg/ml; TENE 8 μg/ml) 
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Fig. 71: Chromatogram of standard 9 (MET 225μg/ml; TENE 9 μg/ml) 
 
Fig. 72: Chromatogram of standard 10 (MET 250μg/ml; TENE 10 μg/ml) 
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7.  SUMMARY AND CONCLUSION 
 Literature survey reveals no RP-HPLC and HPTLC methods for the 
simultaneous determination of metformin and teneligliptin in pharmaceutical 
dosage form. An attempt was made to develop validated methods like RP-HPLC 
and HPTLC for the simultaneous analysis of metformin and teneligliptin in 
combined dosage form. 
7.1.  HPTLC METHOD 
 For the determination of metformin and teneligliptin by HPTLC method 
different mobile phase systems were tried. It was found that a system comprising 
of methanol: tetrahydrofuran: ammonia (7: 3: 0.1, v/v/v) gave good separation 
with symmetric peaks, (Rf value of 0.29 ± 0.02 for metformin and 0.71 ± 0.02 for 
teneligliptin) at the selected wavelength of 258 nm.  The method was validated as 
per ICH guidelines. Calibration curves were plotted with peak areas of standard 
drug versus concentration.  
 Metformin was found to be linear in the concentration range of 6.25 to 
 17.5 g/band. 
 Teneligliptin was found to be linear in the concentration range of 0.25 to 
 7 g/band. 
 The LOD values for metformin and teneligliptin were found to be 0.01 and 
0.1g/band, and their LOQ values were found to be 0.07 and 0.4g/band 
respectively. 
 %RSD values for precision studies were found to be less than 2 which 
shows that the method is precise. 
 Recovery studies were carried out at 80%, 100% and 120% levels. Good 
recovery values show that the method is free from interferences. This method was 
successfully used for the simultaneous determination of metformin and 
teneligliptin from pharmaceutical dosage form. 
Summary & Conclusion 
 
 
Department of Pharmaceutical Analysis  78 
 Peak purity studies of the drugs (peak purity index values close to 1) 
showed that no impurities or degradation products eluted with drug peaks. 
7.2.  RP-HPLC METHOD 
 In RP-HPLC method, optimizations of different chromatographic 
parameters like selection of chromatographic method, detection wavelength, 
selection of mobile phase, mobile phase ratio, etc., were done. A wavelength of 
247 nm was selected for the study. It was found that a system comprising of  
10 mM potassium dihydrogen orthophosphate: methanol (35: 65, v/v) gave good 
resolution and peak characteristics, (retention times of metformin = 3 minutes and 
teneligliptin = 4.6 minutes). The method was validated as per ICH guidelines. 
Calibration curves were plotted with concentration versus peak area. 
 
 Metformin was found to be linear in the concentration range of 25 to  
 250 g/ml. 
 Teneligliptin was found to be linear in the concentration range of 1 to  
 10 g/ml. 
 
The LOD values for metformin and teneligliptin were found to be 5 and  
10 ng/ml, and their LOQ values were found to be 10 and 70 ng/ml respectively.  
 
Stability studies were carried and the drug solutions were found to be 
stable for 5 hours and 24 hours at room temperature and refrigerated conditions, 
respectively. 
 
Recovery studies were carried out at 80%, 100% and 120% levels. Good 
recovery values show that the method is free from interferences. 
 
System suitability parameters like plate number (N), tailing factor (Tf), 
capacity factor (k`), resolution (Rs) and relative standard deviation of peak area for 
repetitive injections were studied and it was found that the values were within the 
limits. 
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 Specificity of the method was studied by degrading the drugs in acidic, 
basic, oxidative and neutral conditions. Peak purity studies of the drugs  
(peak purity index values close to 1) showed that no impurities or degradation 
products eluted with drug peaks when compared to the standards. This indicates 
that the developed method is specific for the simultaneous determination of the 
drugs. 
 Summary of the method development studies is given in the table 22. 
 RP-HPLC and HPTLC methods were found to be simple, precise, specific 
and accurate. The developed methods were successfully validated according to 
ICH guidelines and hence these methods can be used for the simultaneous 
determination of metformin and teneligliptin from pharmaceutical dosage forms. 
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Table 22: Comparison of developed methods (HPTLC and RP-HPLC) 
PARAMETERS 
HPTLC RP-HPLC 
METFORMIN TENELIGLIPTIN METFORMIN TENELIGLIPTIN 
Linearity (Concentrations) 6.25 – 17.5 g/band 0.25 – 0.7 g/band 25 – 250 g/ml 1 – 10 g/ml 
Correlation coefficient (r2) 0.9991 0.9981 0.9991 0.9998 
Accuracy (Recovery) 
80% 
100% 
120% 
 
99.62 
101.25 
100.92 
 
99.99 
100.98 
101.06 
 
99.9 
99.78 
103.81 
 
99.43 
100.27 
99.66 
 % RSD 
Repeatability 
Intraday precision 
Inter day precision 
0.13 
0.32 
0.39 
0.7 
1.5 
1.29 
0.09 
0.71 
0.57 
0.43 
0.37 
0.55 
LOD 0.07 g/band 0.1 g/band 5 ng/ml 10 ng/ml 
LOQ 0.1 g/band 0.4 g/band 10 ng/ml 70 ng/ml 
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7.3.  STATISTICAL EVALUATION19, 20 
 The above developed analytical methods were statistically compared by 
student t test using Graph Pad Instat software. This results shows that there is no 
significant difference among these methods. Hence, the developed methods can be 
used for routine analysis of metformin and teneligliptin from pharmaceutical 
dosage form, table 23. 
Table 23: Statistical comparisons between developed methods 
Methods Metformin Teneligliptin 
RP-HPLC vs HPTLC 
 
tc = 0.3937 
P value = 0.0942 
 
tc  = 12.626 
P value = 0.4846 
tc = calculated ‘t’ value; tt = table ‘t’ values (tt  = 2.228  for n = 6) 
Hypothesis (Ho): no statistical difference exists between two methods. tc <  tt: Ho 
Hypothesis is accepted (P > 0.05) 
The two-tailed P value was considered no significant. 
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